ERYTECH appoints Allene Diaz to its Board of Directors

– FRANCE, Lyon – ERYTECH Pharma (Euronext Paris:ERYP) (ERYP.PA) (EYRYY), a French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced the appointment of Allene M. Diaz to its Board of Directors as a nonvoting member (censeur). As censeur, Ms. Diaz will initially attend all Board of Directors meetings in an advisory capacity. ERYTECH intends to nominate her to serve as a voting Board member in January 2017 in anticipation to the next general shareholders’ meeting. Ms. Diaz has more than 20 years of experience in the global biopharmaceutical and biotechnology industry and has held management and executive positions at leading biopharmaceutical companies, including TESARO, Merck Serono, Biogen Idec and Pfizer.

“Allene’s extensive experience in the biopharmaceutical industry, and oncology specifically, will be invaluable to us at this important time of our clinical development,” commented Gil Beyen, Chief Executive Officer and Chairman of the Board of ERYTECH Pharma. “We welcome Allene to our Board of Directors and look forward to the contributions she will make and leveraging her strategic counsel as we work toward advancing our ERYCAPS technology platform-based products.”

“I am delighted to be joining ERYTECH‘s Board of Directors,” said Ms. Diaz. “I believe ERYTECH is well positioned for success with its promising pipeline of early and late-stage product candidates, proprietary red-blood cell technology and strong leadership team. It is an exciting time for the Company as it continues to work toward commercialization of its lead product GRASPA® in Europe, is actively enrolling patients in three clinical trials, and is developing new clinical studies both in Europe and in the United States. I look forward to working closely with the Board and leadership team to contribute to the achievement of key developmental milestones and supporting the Company’s plans in this next phase of growth.”

Ms. Diaz has significant experience in the biopharmaceutical industry with broad cross-functional expertise in sales, medical affairs, marketing, new product planning, portfolio planning, strategic planning, and market access. She currently serves as Senior Vice President, Global Commercial Development at TESARO, where she focuses on development of commercialization strategies across therapeutic assets, evaluates the commercial impact of clinical development options, and assesses potential in-licensing opportunities. Prior to joining TESARO, Ms. Diaz served as Senior Vice President, Managed Markets at EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, where she developed market access strategies and tactics for reimbursement by commercial and government payers across the EMD Serono portfolio. Previously, Ms. Diaz also held the positions of Senior Vice President, Head of Oncology Commercial, U.S. and Vice President, Oncology Marketing at EMD Serono, where she oversaw the commercial pre-launch efforts for EMD Serono’s oncology products. Ms. Diaz has held executive, management and/or line positions at other leading companies including Amylin Pharmaceuticals, Cancervax Corporation, Biogen Idec, Pfizer, and Parke-Davis Pharmaceuticals.

Ms. Diaz graduated cum laude with a Bachelor of Science from Florida State University. She has also attended executive education programs at the London School of Business and Finance, University of Michigan School of Business, China Europe International Business School (Shanghai, China), Stanford University School of Business and INSEAD (Fontainebleau, France).


Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. ERYTECH has recently filed for European Marketing Authorization for its lead product candidate, eryaspase, also known as eryasp and under the trade name GRASPA®, following positive efficacy and safety results from its completed Phase 2/3 pivotal clinical trial of GRASPA in Europe in children and adults with relapsed or refractory ALL. ERYTECH also has an ongoing Phase 1 clinical trial of eryaspase in the United States in adults with newly diagnosed ALL, and a Phase 2b clinical trial of GRASPA in Europe in elderly patients with newly diagnosed AML, each in combination with chemotherapy.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>